The role of the ß-agonist (beta agonist) pathway in controlling the body's fat
stores, muscle hypertrophy (growth), the body's response to exercise and even muscle fiber type has been brought
to light in the last 10 years through the efforts of hundreds of scientists with literally thousands of
papers being published on the subject. Clearly, the ß-agonist pathway is one of the most important
signalling pathways in the body. To understand how the ß-agonist pathway works and what role
Caffeine, Ephedrine and Aspirin plays in the system one must first understand what a ß-agonist
is and what they do.
On the surfaces of many of the cells of the body (for our purposes the most important tissues are
muscle and fat cells) are located b receptors. These b receptors bind b-agonists (adrenaline and
noradrenaline). When a ß-agonist is bound to a b receptor, the receptor initiates a series
of chemical reactions that results in the production of a chemical messenger called C-AMP. This C-AMP
then activates enzymes that phosphorylate proteins. Why is this important? Well, many of these proteins
are enzymes and phosphorylation activates some enzymes and de-acitvates others. In fat cells enzymes
are activated that induce lipolysis (fat breakdown). In muscle cells enzymes are activated that
increase metabolism and cause a host of other important reactions which control muscle growth,
fiber type and enzyme concentration.
So, how do ephedrine, caffeine and aspirin fit into this pathway? Ephedrine enhances ß-agonist
production and even acts as a ß-agonist itself. Caffeine inhibits the breakdown of C-AMP.
Aspirin inhibits the negative feedback loop that would reduce ß-agonist production.
So taken together these agents enhance three to four different steps in the ß-agonist
pathway.
Ephedrine's role as a lipolytic agent (one that breaks down body fat to be used as energy) has
been known for some time. It has been shown that
ephedrine when taken in therapeutic doses is mildly effective in the management of obesity.
The problem was that the initial lipolytic effects of ephedrine were soon diminished as
other steps in the pathway were reduced in a negative feedback cycle. In an effort to enhance
these steps that were being downregulated due to negative feedback, scientists added caffeine
and aspirin to the regime. The result was a very effective combination in the management of
obesity (dosages given were 20mg ephedrine, 300mg caffeine, and 80mg aspirin, roughly equivalent
to one typical ephedrine tablet, a cup of coffee and one aspirin). In fact, not only did the
results (lipolysis) not decrease over time as with most drugs, but they actually increased
with time. The effects of the combination of ephedrine, caffeine and aspirin were categorized
into desirable and undesirable effects. The desirable effects were lipolysis and protein
sparing (subjects on the drug combination retained more muscle mass while dieting than the
subjects on placebo). Again, these desirable effects did not diminish over time. The
undesirable effects, increased heart rate and muscle tremors, lasted only a few days and
never returned. In fact, after 1 year of supplementation subjects were experiencing no side
effects but were still experiencing the desired effects of lipolysis and protein sparing.
To date it has not been determined if the ephedrine, caffeine and aspirin combination can
enhance muscle growth and fat loss in healthy, exercising adults. However, based on what
we know about the ß-agonist system, it is certainly possible. It is important to
note, however, that a small handful of subjects among the large subject pool had to drop
out of the study due to an intolerance to the supplementation regime. So it appears that
most people can use the ephedrine, caffeine and aspirin combination with no problems, while
a small handful of people may be intolerant. A consultation with a physician is suggested
before beginning this supplementation regime.
The ß-agonist pathway may effect processes other than muscle sparing and fat loss.
In fact in chickens ß-agonists were shown to be stronger growth promoting agents than
steroids (believe it or not but poultry science folks are doing a lot of research trying to
produce more muscular chickens since the muscle is the meat that we eat).
In fact ß-agonists seem to produce muscle growth
without the stimulus of exercise, something steroids have failed to do. However ß-agonists
are not as effective in rats and the effects on humans is unknown. The ß-agonist
clenbuterol can cause slow twitch muscle fibers to be converted to fast twitch fibers. It
can also prevent muscle atrophy due to disuse. Other studies have shown that b-antagonists
(agents that block b-receptors and prevent them from functioning) cause muscles to shift
from fast twitch to slow twitch and cause muscle atrophy (muscle wasting or breakdown). These studies indicate
that ß-agonists might play an important role in the maintenance of fast twitch muscle
fibers and in maintaining and perhaps increasing muscle mass. It may be no coincidence then
that large amounts of ß-agonists (adrenaline and noradrenaline) are produced during
high intensity training sessions. Perhaps these ß-agonists are necessary in initiating
the muscle growth stimulus.
It is important to note that some ß-agonists can be dangerous (for example clenbuterol
and cocaine) and illegal and these substances are not recommended. Also, as mentioned earlier,
although the ß-agonist combination of caffeine, ephedrine and aspirin appears to be safe
(and of course legal) a small number of people are intolerant and consultation with a physician
is suggested. Everyone should visit there doctor prior to using any of these substances for a clean
bill of health.
Some Suggested Reading
Astrup, A., Breum, L., Toubro, S., Hein, P., and Quaade, F., (1992) The effect and safety of
an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subject
on an energy restricted diet. A double blind trial, International Journal of Obesity, 16, 269-277.
Dullo,A., Seydoux, J., and Girardier, L., (1992) Potentiation of the thermogenic antiobesity
effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase
inhibition, Metabolism, 41, (11) .
Maltin, C., Delday, M., Hay, S., Smith, F., Lobley, G., and Reeds, Pl, (1987) The effect of
the anabolic agent, clenbuterol, on overloaded rat skeletal muscle, Bioscience Rep., 7, (2), 149-143.